Journal article
Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies
I Verbrugge, J Hagekyriakou, LL Sharp, M Galli, A West, NM McLaughlin, H Duret, H Yagita, RW Johnstone, MJ Smyth, NM Haynes
Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2012
Abstract
It is becoming increasingly evident that radiotherapy may benefit from coincident or subsequent immunotherapy. In this study, we examined whether the antitumor effects of radiotherapy, in established triple-negative breast tumors could be enhanced with combinations of clinically relevant monoclonal antibodies (mAb), designed to stimulate immunity [anti-(α)-CD137, α-CD40] or relieve immunosuppression [α-programmed death (PD)-1]. While the concomitant targeting of the costimulatory molecules CD137 and CD40 enhanced the antitumor effects of radiotherapy and promoted the rejection of subcutaneous BALB/c-derived 4T1.2 tumors, this novel combination was noncurative in mice bearing established C57B..
View full abstractGrants
Awarded by Japan Society for the Promotion of Science
Funding Acknowledgements
This work was financially supported by the Dutch Cancer Society to I. Verbrugge (NKI2009-4446); National Health and Medical Research Council of Australia (NHMRC) program grants, Susan G. Komen Breast Cancer Foundation, Victorian Cancer Agency (to M.J Smyth and R. W Johnstone); Victorian Breast Cancer Research Consortium (to R. W. Johnstone, M.J. Smyth, and N.M. Haynes); Leukemia Foundation of Australia, Australian Rotary Health Foundation (to R. W. Johnstone); an NHMRC Fellowship (to M.J. Smyth); Pfizer, Cancer Australia and a Cure Cancer Australia grant (to N.M. Haynes).